Wellington Management Group LLP increased its holdings in HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 24.9% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 848,940 shares of the company's stock after acquiring an additional 169,337 shares during the quarter. Wellington Management Group LLP owned about 0.98% of HealthEquity worth $75,021,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Hancock Whitney Corp lifted its stake in HealthEquity by 1.0% in the fourth quarter. Hancock Whitney Corp now owns 13,326 shares of the company's stock worth $1,279,000 after acquiring an additional 133 shares during the period. Xponance Inc. raised its holdings in HealthEquity by 1.1% in the first quarter. Xponance Inc. now owns 12,412 shares of the company's stock worth $1,097,000 after purchasing an additional 136 shares in the last quarter. Fifth Third Bancorp raised its holdings in HealthEquity by 17.5% in the first quarter. Fifth Third Bancorp now owns 955 shares of the company's stock worth $84,000 after purchasing an additional 142 shares in the last quarter. Greenleaf Trust raised its holdings in HealthEquity by 7.8% in the first quarter. Greenleaf Trust now owns 2,407 shares of the company's stock worth $213,000 after purchasing an additional 175 shares in the last quarter. Finally, State of Alaska Department of Revenue raised its holdings in HealthEquity by 1.8% in the first quarter. State of Alaska Department of Revenue now owns 10,136 shares of the company's stock worth $895,000 after purchasing an additional 180 shares in the last quarter. Hedge funds and other institutional investors own 99.55% of the company's stock.
Insider Buying and Selling
In related news, Director Jon Kessler sold 97,767 shares of HealthEquity stock in a transaction dated Friday, June 6th. The stock was sold at an average price of $112.05, for a total value of $10,954,792.35. Following the completion of the sale, the director directly owned 75,000 shares in the company, valued at approximately $8,403,750. This trade represents a 56.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael Henry Fiore sold 1,794 shares of HealthEquity stock in a transaction dated Monday, July 7th. The stock was sold at an average price of $101.73, for a total value of $182,503.62. Following the completion of the sale, the executive vice president owned 53,225 shares of the company's stock, valued at $5,414,579.25. The trade was a 3.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 291,744 shares of company stock worth $32,705,007. 1.50% of the stock is owned by corporate insiders.
Wall Street Analyst Weigh In
A number of research firms have issued reports on HQY. JMP Securities increased their price objective on HealthEquity from $110.00 to $117.00 and gave the stock a "market outperform" rating in a report on Wednesday, June 4th. Royal Bank Of Canada increased their price objective on HealthEquity from $112.00 to $117.00 and gave the stock an "outperform" rating in a report on Wednesday, June 4th. Barrington Research increased their price objective on HealthEquity from $112.00 to $125.00 and gave the stock an "outperform" rating in a report on Thursday, June 5th. Deutsche Bank Aktiengesellschaft increased their price objective on HealthEquity from $98.00 to $115.00 and gave the stock a "buy" rating in a report on Thursday, June 5th. Finally, Raymond James Financial reiterated a "strong-buy" rating and issued a $120.00 price objective (up previously from $115.00) on shares of HealthEquity in a report on Tuesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $118.55.
Check Out Our Latest Report on HQY
HealthEquity Price Performance
Shares of NASDAQ:HQY opened at $89.82 on Friday. HealthEquity, Inc. has a 1-year low of $73.84 and a 1-year high of $116.65. The company has a debt-to-equity ratio of 0.50, a current ratio of 4.06 and a quick ratio of 4.06. The business has a fifty day moving average price of $96.78 and a 200-day moving average price of $96.64. The company has a market capitalization of $7.77 billion, a PE ratio of 65.56, a PEG ratio of 1.41 and a beta of 0.54.
HealthEquity (NASDAQ:HQY - Get Free Report) last issued its quarterly earnings results on Tuesday, June 3rd. The company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.81 by $0.16. HealthEquity had a return on equity of 11.01% and a net margin of 9.80%.The firm had revenue of $330.80 million during the quarter, compared to the consensus estimate of $322.25 million. During the same period last year, the company earned $0.80 earnings per share. HealthEquity has set its FY 2026 guidance at 3.610-3.78 EPS. As a group, equities analysts expect that HealthEquity, Inc. will post 2.32 EPS for the current fiscal year.
HealthEquity Profile
(
Free Report)
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider HealthEquity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HealthEquity wasn't on the list.
While HealthEquity currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.